Cyclins, cyclin-dependent kinases (CDKs) and cyclindependent kinase inhibitors (CKIs) play a key role in cell cycle control. To achieve an orderly progression through the cell cycle, different cyclin -CDK complexes need to be activated and deactivated at appropriate times. Cyclin D-CDK4 is one of the complexes that promotes cell passage through the G1 phase of the cell cycle. It increases the phosphorylation state of the retinoblastoma protein which then releases transcription factors (e.g. E2F) essential for progression into the S-phase (reviewed by Sherr, 1993; Hartwell and Kastan, 1994; Hunter and pines, 1994 al., 1994).
Cyclins, cyclin-dependent kinases (CDKs) and cyclindependent kinase inhibitors (CKIs) play a key role in cell cycle control. To achieve an orderly progression through the cell cycle, different cyclin -CDK complexes need to be activated and deactivated at appropriate times. Cyclin D-CDK4 is one of the complexes that promotes cell passage through the G1 phase of the cell cycle. It increases the phosphorylation state of the retinoblastoma protein which then releases transcription factors (e.g. E2F) essential for progression into the S-phase (reviewed by Sherr, 1993; Hartwell and Kastan, 1994; Hunter and pines, 1994) . Changes in the amount or composition of CDKs or their inhibitors may lead to loss of cell cycle control and thus to uncontrolled cell growth.
One of the inhibitors of cyclin D -CDK4 as well as of other cyclin -CDK complexes throughout the whole cell cycle is the p21 protein, encoded by the WAF1 (CIPI/SDI1) gene (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) . Upon genotoxic damage, expression of p21 is induced through the transcriptional activation by TP53Wt (El-Deiry et al., 1994) . The TP53 gene is located on chromosome 17pl3.1 and mutation of this gene is the most common genetic abnormality yet found in human cancers. The prevalence of TP53 mutations varies among tumour types with roughly 44% of ovarian tumours being mutated (reviewed by Greenblatt et al., 1994) .
Another negative regulator of cyclin D-CDK4/6 activity is the p16 protein, encoded by the CDKN2 (MTSIpl6in'k4/ CDK4I) gene (Serrano et al., 1993; Nobori et al., 1994 (1979) classification the primary and metastatic carcinomas were subtyped into serous (n = 14 primary, n = 5 metastatic), mucinous (n = 4), endometroid (n = 7), clear cell (n = 2), mixed (n = 3), poorly differentiated (n = 1) and unknown (n = 1). Figure 1 and Table I respectively.
Briefly, exon 1 was amplified by PCR using intronic primer pairs (Okamoto et al., 1994) as shown in Table I . Exon 2 was amplified using primer pair M2-U/M2-D, generating a 522 bp fragment. To enhance specificity and to generate smaller fragments, two nested PCRs were carried out using primer pairs A1/A2 and B1/M2-D. About 200 ng genomic DNA was used for PCR. Amplification was performed in the presence of 10% dimethyl sulphoxide ( We have studied alterations in exons 1 and 2 of the CDKN2 gene in 32 primary and five metastatic ovarian adenocarcinomas and in five ovarian cancer cell lines using PCR-SSCP and sequencing techniques.
Two cell lines, SK-OV-3 and HOC-7, showed alterations in the CDKN2 gene. No PCR products for exon 1 and 2 could be generated using the cell line SK-OV-3, indicating that the CDKN2 gene is homozygously deleted in this cell line. The integrity of the DNA was confirmed by a successful amplification of TP53 (exons 5-8). The cell line HOC-7 was found to have a 16 bp deletion in exon 2 of the CDKN2 gene. This deletion removes nucleotides at positions 163 -178, thereby placing the sequence in a different reading frame and introducing a stop codon 256 bp downstream from the deletion. In addition, this cell line also has a mutation (T-.A) 36 bp downstream of this deletion.
Among the 32 primary tumours examined a total of nine (28%) altered migration patterns were detected (Figure 1 and Table II ). Two mobility shifts correlated with silent mutations in exon 1 (codon 23:GGT-÷GGA) and exon 2 (codon 67:GGC--GGT; Figure 2 ). The remaining seven (22%) mobility shifts represented a common polymorphism (GCG-+ACG; Figure 2 ), substituting a threonine for an alanine at codon 148. The metastatic tumour specimens, however, revealed no mobility shifts by SSCP.
With respect to TP53 gene alterations, 13 out of 32 (41%) primary tumour specimens and four out of five (80%) metastatic tumour specimens showed altered migration patterns on SSCP. Of the seven tumours having a polymorphism in the CDKN2 gene three tumour specimens showed an alteration in the TP53 gene. DNA sequencing analysis showed that two mutations occurred in exon 7
(Arg248Trp and Arg248Leu), whereas the third mutation was found in exon 6 (Ilel95Thr ; Table II ). Of the two tumours having a silent CDKN2 gene mutation, one also showed a mutation in exon 6 (Arg2l3stop) of the TP53 gene.
Discussion
To determine whether alterations of the CDKN2 gene may be critical in the formation of ovarian cancer, we have analysed primary and metastatic ovarian adenocarcinomas and ovarian cancer cell lines for the presence of CDKN2 gene alterations. One of the five cell lines tested, SK-OV-3, was found to be homozygously deleted for the CDKN2 gene, whereas another cell line, HOC-7, showed a partial deletion of 16 bp in exon 2, resulting in a frameshift and a premature stop codon. Okamoto et al. (1994) (Hayashi and Yandell, 1993) . Moreover, a normal TP53 mutation spectrum was observed since, of all tumours studied, 46% showed a TP53 alteration as determined by SSCP. A recent review by Shelling et al. (1995) reported that 44% (46 out of 105) ovarian tumours showed TP53 mutations, measured by SSCP.
A low frequency of CDKN2 gene alteration in tumours and a higher frequency in cell lines has also been described in tumours of the breast (Xu et al., 1994; Berns et al., 1995) , head and neck (Zhang et al., 1994; Lydiatt et al., 1995) , lung, bladder, kidney, brain and colon (Cairns et al., 1994; Spruck et al., 1994) . In contrast, homozygous deletions and/or mutations occur more often in mesotheliomas (Cheng et al., 1994) , melanomas (Hussussian et al., 1994) , non-small-cell lung carcinomas (Hayashi et al., 1994) , glioblastomas (Schmidt et al., 1994) and several other tumours (Mori et al., 1994; Caldas et al., 1994) .
This study does not rule out a putative role of methylation of the CDKN2 gene in ovarian cancer. De novo methylation of the 5'CpG island of CDKN2 is a frequent abnormality in non-small-cell lung cancer, gliomas, head and neck squamous cell carcinoma, breast and colon cancer (Herman et al., 1995; Merlo et al., 1995) . This methylation could lead to lack of expression of CDKN2 protein causing loss of cell cycle control. This will be a subject for further study.
In conclusion, alterations in the CDKN2 gene are infrequent in both primary and metastatic ovarian adenocarcinomas, suggesting that CDKN2 gene mutations play no significant role in the initiation or progression of ovarian cancer. A study on an association with prognosis is not attainable owing to the low prevalence of CDKN2 mutations. Since LOH at 9p2l has been reported in up to CDKN2 gene alterations in ovarian cancer M Schuyer et a! x 1073 50% of primary epithelial ovarian tumours (ChenevixTrench et al., 1994; Weitzel et al., 1994) , one or more other tumour-suppressor genes may be present in the region of 9p21.
